Prognostic value of positron emission tomography (PET) with fluorine-18 fluorodeoxyglucose ([18F]FDG) after first-line chemotherapy in non-Hodgkin's lymphoma: is [18F]FDG-PET a valid alternative to conventional diagnostic methods?
about
A 61-year-old man with dyspepsia and weight lossPredictive Efficacy of Interim Positron Emission Tomography/Computed Tomography (PET/CT) for the Treatment of Aggressive LymphomaTumor Burden Assessed by the Maximum Standardized Uptake Value and Greatest Diameter on FDG-PET Predicts Prognosis in Untreated Diffuse Large B-cell Lymphoma.Coincidence of follicular lymphoma and hurtle cell thyroid carcinoma in a patient at presentation: which one is the source of bone metastasis? Case report and review of the literature.My treatment approach to patients with diffuse large B-cell lymphoma.Standard and novel imaging methods for multiple myeloma: correlates with prognostic laboratory variables including gene expression profiling data.Prognostic factors for diffuse large B-cell lymphoma in the R(X)CHOP era.The role of FDG-PET imaging as a prognostic marker of outcome in primary mediastinal B-cell lymphoma.18-Fluoro-deoxyglucose positron emission tomography report interpretation as predictor of outcome in diffuse large B-cell lymphoma including analysis of 'indeterminate' reports.Use of subsequent PET/CT in diffuse large B-cell lymphoma patients in complete remission following primary therapyRole of frontline autologous stem cell transplantation in young, high-risk diffuse large B-cell lymphoma patients.PET in lymphoma.Results of the randomized international FAB/LMB96 trial for intermediate risk B-cell non-Hodgkin lymphoma in children and adolescents: it is possible to reduce treatment for the early responding patients.Maximum standardized uptake value on positron emission tomography/computed tomography predicts clinical outcome in patients with relapsed or refractory diffuse large B-cell lymphoma.Correlating metabolic and anatomic responses of primary lung cancers to radiotherapy by combined F-18 FDG PET-CT imaging.Positron emission tomography scanning in the assessment of patients with lymphoma.[F-18]-Fluoro-2-deoxy-D: -glucose positron emission tomography as a tool for early detection of immunotherapy response in a murine B cell lymphoma model.A Systematic Comparison of 18F-C-SNAT to Established Radiotracer Imaging Agents for the Detection of Tumor Response to Treatment.Qualitative visual trichotomous assessment improves the value of fluorine-18 fluorodeoxyglucose positron emission tomography/computed tomography in predicting the prognosis of diffuse large B-cell lymphomaPositron emission tomographic scans in lymphoma: convention and controversy.Response-adapted therapy for aggressive non-Hodgkin's lymphomas based on early [18F] FDG-PET scanning: ECOG-ACRIN Cancer Research Group study (E3404)Treatment with the MEK inhibitor U0126 induces decreased hyperpolarized pyruvate to lactate conversion in breast, but not prostate, cancer cells.Lymphomatous involvement of gastrointestinal tract: evaluation by positron emission tomography with (18)F-fluorodeoxyglucosePredictive role of positron emission tomography (PET) in the outcome of lymphoma patientsPathological Fractures in Primary Non-Hodgkin's Lymphoma of the Bone: A Case Series with Review of the LiteratureEarly post transplant (F-18) 2-fluoro-2-deoxyglucose positron emission tomography does not predict outcome for patients undergoing auto-SCT in non-Hodgkin and Hodgkin lymphoma.Evaluation of cancer treatment in the abdomen: Trends and advances.Risk-adapted dose-dense immunochemotherapy determined by interim FDG-PET in Advanced-stage diffuse large B-Cell lymphoma.The prognostic value of PET and PET/CT in cervical cancerFDG PET and risk-adapted therapy in Hodgkin's and non-Hodgkin's lymphoma.F-18-fluoro-deoxy-glucose positron emission tomography in the assessment of peripheral T-cell lymphomas.Overview of early response assessment in lymphoma with FDG-PET.The utility of body FDG PET in staging primary central nervous system lymphomaNewer Diagnostic Methods in OncologyState-of-the-Art Research on "Lymphomas: Role of Molecular Imaging for Staging, Prognostic Evaluation, and Treatment Response".A comparison between radiolabeled fluorodeoxyglucose uptake and hyperpolarized (13)C-labeled pyruvate utilization as methods for detecting tumor response to treatmentRole of imaging in the staging and response assessment of lymphoma: consensus of the International Conference on Malignant Lymphomas Imaging Working Group.Clinical implications of positron emission tomography-negative residual computed tomography masses after chemotherapy for diffuse large B-cell lymphoma.High incidence of false-positive PET scans in patients with aggressive non-Hodgkin's lymphoma treated with rituximab-containing regimens.F18-fluorodeoxyglucose positron emission tomography in the context of other imaging techniques and prognostic factors in multiple myeloma.
P2860
Q24813742-3F8AD652-0444-4F9F-9B78-8C9C60105595Q26771059-477DCBD6-05EB-4E6E-9EA5-DEEF7AE42A99Q33704212-6C05418D-06F5-4BBE-9FB3-D8EC14D89EC1Q33760931-AAE9A051-FF25-4A86-94C4-C7DC0B507CB4Q34251964-CB65A025-E0EB-4C76-AB7C-1B4B761EE6BEQ34316959-6C2F9BDC-B216-41F9-9C6D-72BF8AEF68D2Q34882773-DD6627E1-6429-4906-9825-DA877183FA1BQ35032285-DB3ED3A3-DCBF-47CE-B5FC-A6421586DFD9Q35064885-98055119-EBFA-4E7D-8F84-69988E967CB7Q35178725-060379B8-149A-41BA-B32D-E62A71C9A237Q35626262-1DE64BB6-14FD-471E-B4E4-DCEBA4775BB0Q35650641-6EE25FA8-3BED-4922-A849-5A1CC7E435CBQ35750990-B01B7C06-9D64-484E-98D8-3F3F2E7C7EFEQ35800656-731004F6-F703-44BB-8EEE-C36CE8DFAE5EQ35843758-C6451C1F-AEAA-4CBE-B612-8812FA9F7CA4Q35843931-4611AA07-4101-4783-87F8-E63621D090C7Q35891382-BE4CC992-516B-40F7-9876-86864FFC7245Q36021562-30E2F999-A49E-41A7-A398-F7B440C089ABQ36121138-0E5A2F5C-FA74-4B26-8C77-E2B5B6F86FFEQ36399538-719B5F8A-3BE2-45AE-89B3-436F455A01D5Q36417808-A5C3B597-5100-432C-823B-B1930AD330AEQ36488080-48924802-B56A-4545-A699-6330D3D1510CQ36497011-E59EB2DB-59CF-4399-BED2-F433F1C92E9AQ36695611-996E5D43-2724-4B73-A576-391A295CB90EQ36740357-C418E4CA-1CFB-4E46-8B1A-87DE1EB3A050Q36747993-F71A64EC-235E-42E7-AB94-952B3FD463EDQ36832118-E05B0E89-A6FD-4019-879D-9E4B9648263CQ36836092-F885E223-8C45-4614-BDC7-DC7FF61ED830Q36836254-D7C0E331-C4B5-43F1-A5AB-AD6E6EEDA2C7Q36838768-5326108A-13E5-42A9-94E7-83B5DD36B2E4Q36911500-BA825E47-AFA5-4623-8DDF-266E24F25AD0Q36927213-3DE3AB1D-6BAF-41FD-A4D2-C674DE3FD11DQ37036944-620ADD5A-7766-4AEB-996F-B88D45357141Q37040280-814DC554-F938-4265-802C-706FB668C508Q37144956-80BE3553-CD44-404F-84E8-258186EDD932Q37200476-BD169C8C-19EC-46FC-A1FF-6A2630AB7E6FQ37240835-9B4CF813-CE15-4B01-BEC1-9DB5CDBC9D36Q37307649-D44EA9A9-CEDC-490B-B2DA-E9806C6AADF0Q37321768-7C0E1315-C836-4B34-B98E-13499F528C57Q37348247-539F6203-1D7D-4B1D-8376-98239713C5BA
P2860
Prognostic value of positron emission tomography (PET) with fluorine-18 fluorodeoxyglucose ([18F]FDG) after first-line chemotherapy in non-Hodgkin's lymphoma: is [18F]FDG-PET a valid alternative to conventional diagnostic methods?
description
2001 nî lūn-bûn
@nan
2001 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2001 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2001年の論文
@ja
2001年論文
@yue
2001年論文
@zh-hant
2001年論文
@zh-hk
2001年論文
@zh-mo
2001年論文
@zh-tw
2001年论文
@wuu
name
Prognostic value of positron e ...... nventional diagnostic methods?
@ast
Prognostic value of positron e ...... nventional diagnostic methods?
@en
type
label
Prognostic value of positron e ...... nventional diagnostic methods?
@ast
Prognostic value of positron e ...... nventional diagnostic methods?
@en
prefLabel
Prognostic value of positron e ...... nventional diagnostic methods?
@ast
Prognostic value of positron e ...... nventional diagnostic methods?
@en
P2093
P1476
Prognostic value of positron e ...... nventional diagnostic methods?
@en
P2093
C De Wolf-Peeters
J Balzarini
L Mortelmans
L Vanuytsel
P Vandenberghe
P304
P356
10.1200/JCO.2001.19.2.414
P407
P577
2001-01-01T00:00:00Z